老年人急性非淋巴细胞白血病化疗疗效观察

TREATMENT OF ACUTE NON-LYMPHOCYTIC LEUKEMIA IN ELDERLY PATIENTS WITH COMBINED CHEMOTHERAPY REGIMENS OF DIFFERENT DOSES

报道了五年间收治的老年急性非淋巴细胞白血病（ＡＮＬＬ）２１例，采用ＤＡ（ＶＰ１６）与ＨＡ（ＶＰ１６）联合化疗，依据不同剂量，将其分为二组，二组总有效率为６６．６％。其中中等剂量组１４例，８例ＣＲ，平均生存时间为２６７天；２例（１８％）ＰＲ：小剂量组７例，２例（２８．５％）ＣＲ，２例（２８．５％）ＰＲ；结果提示：对老年白血病患者治疗应个体化，一般情况好者应在强有力支持治疗情况下采用中等剂量的化疗。

The effect of treatment of acute non lymphocytic leukemia in 21 elderly patients were reported with combined chemotherapy of DA (idarubicin and cytosine arabinoside) with etoposide (VP 16 ) included or excluded, and of HA (Homoharringtonine、Cytosine arabinoside) with Vp16 included or excluded. The patients were divided into two groups in accordance with the doses they received: the middle dose group and the low dose group. The treatment resulted in an average CR of 66.6%. In the middle dose group, 8 of the 14 patients (57.1%) achieved CR and 2 (14%) achieved PR. In the low dose group, 2 of 7 patients (28.5%) achieved CR and 2 (28.5%) achieved PR. The results showed that elderly patients should be treated case by case. With vigorous supportive care the patients well conditioned can endure middle dose chemotherapy, or should receive low dose chemotherapy.